Application 209963
- Type
- NDA
- Sponsor
- GENUS LIFESCIENCES
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GOPRELTO | COCAINE HYDROCHLORIDE | SOLUTION;NASAL | 4% | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N209963-001 | GOPRELTO | COCAINE HYDROCHLORIDE | 4% | SOLUTION / NASAL | RLD, RS | 2017-12-14 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N209963-001 | 10016407 | 2037-02-07 | U-2329 | 2018-07-20 | |
| N209963-001 | 10149843 | 2037-02-07 | U-2478 | 2019-01-10 | |
| N209963-001 | 10149843 | 2037-02-07 | U-2479 | 2019-01-10 | |
| N209963-001 | 10231961 | 2037-02-07 | Drug product | 2019-04-15 | |
| N209963-001 | 10413505 | 2037-02-07 | U-2479 | 2019-10-16 | |
| N209963-001 | 10420760 | 2037-02-07 | U-2478 | 2019-10-23 | |
| N209963-001 | 10857095 | 2037-02-07 | U-3014 | 2021-01-06 | |
| N209963-001 | 10894012 | 2037-02-07 | U-3014 | 2021-02-11 | |
| N209963-001 | 10933060 | 2037-02-07 | U-3014 | 2021-04-01 | |
| N209963-001 | 10973811 | 2037-02-07 | U-2226 | 2021-05-13 | |
| N209963-001 | 10987347 | 2037-02-07 | U-2225 | 2021-05-27 | |
| N209963-001 | 11040032 | 2037-02-07 | Drug product | 2021-12-09 | |
| N209963-001 | 9867815 | 2037-02-07 | U-2225 | 2018-01-31 | |
| N209963-001 | 9867815 | 2037-02-07 | U-2226 | 2018-01-31 | |
| N209963-001 | 9867815 | 2037-02-07 | U-2227 | 2018-01-31 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 04:53 UTC | 2022-10 | N209963-001 | GOPRELTO | 4% | SOLUTION / NASAL | RLD, RS | 2017-12-14 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | N209963-001 | GOPRELTO | 4% | SOLUTION / NASAL | RLD, RS | 2017-12-14 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N209963-001 | GOPRELTO | 4% | SOLUTION / NASAL | RLD, RS | 2017-12-14 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N209963-001 | GOPRELTO | 4% | SOLUTION / NASAL | RLD, RS | 2017-12-14 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10016407 | 2037-02-07 | U-2329 | 2018-07-20 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10149843 | 2037-02-07 | U-2479 | 2019-01-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10149843 | 2037-02-07 | U-2478 | 2019-01-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10231961 | 2037-02-07 | Drug product | 2019-04-15 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10413505 | 2037-02-07 | U-2479 | 2019-10-16 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10420760 | 2037-02-07 | U-2478 | 2019-10-23 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10857095 | 2037-02-07 | U-3014 | 2021-01-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10894012 | 2037-02-07 | U-3014 | 2021-02-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10933060 | 2037-02-07 | U-3014 | 2021-04-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10973811 | 2037-02-07 | U-2226 | 2021-05-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 10987347 | 2037-02-07 | U-2225 | 2021-05-27 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 11040032 | 2037-02-07 | Drug product | 2021-12-09 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 9867815 | 2037-02-07 | U-2225 | 2018-01-31 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 9867815 | 2037-02-07 | U-2226 | 2018-01-31 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N209963-001 | 9867815 | 2037-02-07 | U-2227 | 2018-01-31 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10016407 | 2037-02-07 | U-2329 | 2018-07-20 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10149843 | 2037-02-07 | U-2479 | 2019-01-10 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10149843 | 2037-02-07 | U-2478 | 2019-01-10 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10231961 | 2037-02-07 | Drug product | 2019-04-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10413505 | 2037-02-07 | U-2479 | 2019-10-16 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10420760 | 2037-02-07 | U-2478 | 2019-10-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10857095 | 2037-02-07 | U-3014 | 2021-01-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10894012 | 2037-02-07 | U-3014 | 2021-02-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10933060 | 2037-02-07 | U-3014 | 2021-04-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10973811 | 2037-02-07 | U-2226 | 2021-05-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 10987347 | 2037-02-07 | U-2225 | 2021-05-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 11040032 | 2037-02-07 | Drug product | 2021-12-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 9867815 | 2037-02-07 | U-2225 | 2018-01-31 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 9867815 | 2037-02-07 | U-2226 | 2018-01-31 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209963-001 | 9867815 | 2037-02-07 | U-2227 | 2018-01-31 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10016407 | 2037-02-07 | U-2329 | 2018-07-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10149843 | 2037-02-07 | U-2479 | 2019-01-10 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10149843 | 2037-02-07 | U-2478 | 2019-01-10 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10231961 | 2037-02-07 | Drug product | 2019-04-15 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10413505 | 2037-02-07 | U-2479 | 2019-10-16 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10420760 | 2037-02-07 | U-2478 | 2019-10-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10857095 | 2037-02-07 | U-3014 | 2021-01-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10894012 | 2037-02-07 | U-3014 | 2021-02-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10933060 | 2037-02-07 | U-3014 | 2021-04-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209963-001 | 10973811 | 2037-02-07 | U-2226 | 2021-05-13 | caaa826d4ba7… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N209963-001 | NCE | 2022-12-14 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N209963-001 | NCE | 2022-12-14 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N209963-001 | NCE | 2022-12-14 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N209963-001 | NCE | 2022-12-14 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N209963-001 | NCE | 2022-12-14 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N209963-001 | NCE | 2022-12-14 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N209963-001 | NCE | 2022-12-14 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N209963-001 | NCE | 2022-12-14 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N209963-001 | NCE | 2022-12-14 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N209963-001 | NCE | 2022-12-14 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N209963-001 | NCE | 2022-12-14 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N209963-001 | NCE | 2022-12-14 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N209963-001 | NCE | 2022-12-14 | ea99ee380514… |
| 2023-01-26 05:58 UTC | 2023-01 | N209963-001 | NCE | 2022-12-14 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N209963-001 | NCE | 2022-12-14 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N209963-001 | NCE | 2022-12-14 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | N209963-001 | NCE | 2022-12-14 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N209963-001 | NCE | 2022-12-14 | cb3db0bc1861… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Goprelto | COCAINE HYDROCHLORIDE | LXO US Inc. | 0f897764-fe30-090a-e063-6294a90af106 | 2024-11-06 | Boxed warning, Warnings, Adverse reactions | 209963 NDA209963 |
| COCAINE HYDROCHLORIDE | COCAINE HYDROCHLORIDE | LXO US INC. | 0fb0298f-9756-26e8-e063-6294a90ae8f2 | 2024-01-25 | Boxed warning, Warnings, Adverse reactions | 209963 NDA209963 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 64950-359 | GOPRELTO | cocaine hydrochloride | Genus Lifesciences Inc. | NDA | Current |
| 64950-359 | GOPRELTO | cocaine hydrochloride | Genus Lifesciences Inc. | NDA | Current |
| 64950-362 | cocaine hydrochloride | cocaine hydrochloride | Genus Lifesciences Inc. | NDA AUTHORIZED GENERIC | Current |
| 64950-362 | cocaine hydrochloride | cocaine hydrochloride | Genus Lifesciences Inc. | NDA AUTHORIZED GENERIC | Current |
| 64950-362 | cocaine hydrochloride | cocaine hydrochloride | Genus Lifesciences Inc. | NDA AUTHORIZED GENERIC | Current |